Compare iShares MSCI Australia ETF (EWA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI Australia ETF trades at $28.63, while TG Therapeutics Inc trades at $54.85 (market cap $8.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals.
| EWA | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.26 | $59.06 |
52-Week Low | $24.95 | $26.39 |
Market Cap | — | $8.64B |
Enterprise Value | — | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $28.625, down 0.3% with a bullish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 72.02 suggesting potential overbought conditions. Recent news highlights Australia's economic developments including fuel excise relief and tax reforms that may impact investor sentiment toward Australian-focused assets.
The outlook remains cautiously optimistic given the bullish technical setup, though limited fundamental data availability requires careful monitoring. Key risks include Australian economic sensitivity and market volatility from geopolitical tensions. Investors should await updated financial metrics for comprehensive fundamental assessment.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
